Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.72 |
| ▸ | MAPK7 | Q13164 | 8/20 | 0.72 |
| ▸ | BRD2 | P25440 | 1/20 | 0.72 |
| ▸ | EP300 | Q09472 | 1/20 | 0.72 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.72 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.72 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.72 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18370037 | 0.85 | BRD4 (0.73) | BRD4MAPK7BRD2EP300BRD3 | |
| SCHEMBL18369999 | 0.83 | BRD4 (1.00) | BRD4MAPK7BRD2EP300BRD3 | |
| SCHEMBL17059837 | 0.83 | MAPK7 (1.00) | BRD4MAPK7BRD2EP300BRD3 | |
| SCHEMBL18369858 | 0.83 | MAPK7 (1.00) | BRD4MAPK7BRD2EP300BRD3 | |
| SCHEMBL17059803 | 0.83 | MAPK7 (1.00) | BRD4MAPK7BRD2EP300BRD3 | |
| SCHEMBL17059906 | 0.80 | BRD4 (0.74) | BRD4MAPK7BRD2EP300BRD3 | |
| SCHEMBL18370000 | 0.78 | BRD4 (1.00) | BRD4MAPK7BRD2EP300BRD3 | |
| SCHEMBL18370039 | 0.78 | MAPK7 (0.88) | BRD4MAPK7BRD2EP300BRD3 | |
| SCHEMBL17059920 | 0.78 | MAPK7 (0.88) | BRD4MAPK7BRD2EP300BRD3 | |
| SCHEMBL17059942 | 0.77 | BRD4 (0.73) | BRD4MAPK7BRD2EP300BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | ACTIVX BIOSCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | ACTIVX BIOSCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| WO-2015129927-A1 | HETEROCYCLIC COMPOUNDS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | BET1, EP300, RBBP5 | BRD4 4/4885MAPK7 58/4885BRD2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.